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Pharmacological treatment of reperfusion injury using insulin and GSK3β inhibition has been shown to be 
cardioprotective, however, their interaction with the endogenous cardioprotective strategy, ischemic 
postconditioning, is not known.  
Design 
Langendorff perfused ex vivo rat hearts were subjected to 30 min of regional ischemia and 120 min of reperfusion. 
For the first 15 min of reperfusion hearts received either vehicle (Ctr), insulin (Ins) or a GSK3β inhibitor 
(SB415286; SB41), with or without interruption of ischemic postconditioning (IPost; 3x30s of global ischemia). 
In addition, the combination of insulin and SB41 for 15 min was assessed.  
Results 
Insulin, SB41 or IPost significantly reduced infarct size versus vehicle treated controls (IPost 33.5±3.3%, Ins 
33.5±3.4%, SB41 30.5±3.0% vs. Ctr 54.7±6.8%, p<0.01). Combining insulin and SB415286 did not confer 
additional cardioprotection compared to the treatments given alone (SB41 + Ins 26.7±3.5%, ns). Conversely, 
combining either of the pharmacological reperfusion treatments with IPost completely abrogated the 
cardioprotection afforded by the treatments separately (Ins + IPost 59.5±3.4% vs. Ins 33.5±3.4% and SB41 + IPost 
50.2±6.6% vs. SB41 30.5±3.0%, both p<0.01), and was associated with blunted Akt, GSK3β and STAT3 
phosphorylation. 
Conclusion 









New developments in clinical cardiology, such as thrombolysis and percutaneous coronary intervention (PCI), 
have allowed rapid restoration of blood flow to the ischemic heart (i.e. reperfusion) and have greatly improved 
survival of patients with acute coronary syndromes. However, despite the necessity of reperfusion to salvage the 
compromised myocardial tissue, reperfusion itself leads to additional myocardial injury (lethal ischemia 
reperfusion injury, IRI) [1]. Currently, no treatments aimed at reducing IRI have successfully translated into 
clinical practice, warranting further research in this area. 
During the last decade, the use of pre-clinical models has substantially enhanced our understanding of the 
mechanisms behind IRI and several cardioprotective strategies have emerged; such as ischemic pre- and post-
conditioning (IPC and IPost), whereby short alternating cycles of ischemia and reperfusion are applied 
immediately before or after a prolonged ischemic event, respectively. In addition, several pharmacological agents 
have been able to mimic this cardioprotection (e.g. insulin), and two common and important signal transduction 
pathways have been identified: The Reperfusion Injury Salvage Kinase (RISK) pathway [2] and the more recent 
Survival Activating Factor Enhancement (SAFE) pathway [3], both recruited at the time of myocardial reperfusion. 
The common mechanism seems to involve stimulation of G-protein coupled receptors on the cell membrane and 
signal transduction via PI3K-Akt and MEK1/2-Erk1/2 (RISK) and/or the innate immune system and activation of 
the JAK/STAT3 (SAFE). These signaling pathways then seem to converge on glycogen synthase kinase 3β 
(GSK3β), which gets phosphorylated, and thus inhibited. This will, via largely unknown mechanisms lead to 
inhibition or delayed opening of the mitochondrial permeability transition pore (mPTP), and cardioprotection [4,5].  
There may, however, be differences in signaling that could allow for synergistic cardioprotective effects, as some 
have reported that insulin and GSK3β signals via a distinct cellular mechanism different from ischemic 
conditioning [5]. The present study therefore explores the potential synergistic effects of combining a tyrosine 







MATERIALS AND METHODS 
Ethical Approval 
88 isolated hearts were studied, and all experiments were approved by the Norwegian State Commission for 
Laboratory Animals, and carried out in accordance with the European Communities Council Directive of 1986 
(2010/63/EU).  
Langendorff perfusion procedure 
Male Wistar rats (Taconic Denmark) fed a standard diet were heparinized (200IU) and anesthetized using 
pentobarbital (50mg/kg i.p). Hearts were rapidly excised and immediately immersed in ice-cold Krebs-Henseleit 
buffer (118mM NaCl, 25mM NaHCO3, 11mM d-Glucose, 4.7mM KCl, 1.22mM MgSO4*7H2O, 1.21mM 
KH2PO4, 1.84mM CaCl2*2H2O; pH 7.4). Within 1 minute hearts were mounted onto the Langendorff perfusion 
system and retrogradely perfused via the aorta with oxygenated Krebs-Henseleit buffer (95%O2 / 5%CO2, 37°C) 
at constant pressure (80mmHg). A silk suture was placed around the left anterior descending (LAD) coronary 
artery, while a water-filled latex balloon connected to a pressure transducer was placed into the left ventricle via 
the left atrium, and the diastolic pressure set to 5-10 mmHg. This measured left ventricular developed pressure 
(LVDP) and heart rate (HR), the product of which yields the rate pressure product (RPP). To monitor temperature, 
a thermo-probe was placed in the pulmonary artery through a small incision. Coronary flow (CF) was measured 
by timed collection of effluents. Regional ischemia (RI) was induced by tightening the silk suture around LAD 
and fastened using a pipette locking mechanism, and reperfusion achieved by loosening the suture.  
Experimental protocol 
All hearts were subjected to 20 min of stabilization followed by 30 min of regional ischemia (RI) and 120 min of 
reperfusion (Fig. 1). Hearts were randomized to receive either vehicle (Ctr), insulin (Ins [0.3 mU/ml]; Novo 
Nordisk A/S, Bagsværd, Denmark) or the GSK3β inhibitor SB415286 (SB41 [3μM]; Tocris Bioscience, UK) for 
15 min at the onset of reperfusion, with or without interruption by 3x30s global ischemia (IPost). In addition, the 
combination of insulin and GSK3β inhibition for 15 min at reperfusion was evaluated. Finally, a parallel set of 
hearts underwent the same protocols, but were harvested at 15 min reperfusion. The atria and right ventricle were 
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removed and the area at risk from the left ventricle was snap frozen in liquid nitrogen for protein determination by 
western blotting (WB, n=3-5 for each group).   
Measurement of ischemic risk zone and infarct size  
At the end of the perfusion protocol LAD was re-occluded by securely tightening the silk suture, followed by 
infusion of a Evans Blue suspension (0.2% (w/v)) to demarcate the risk zone (Duke Scientific Corp., Palo Alto, 
CA, USA). Hearts were frozen (-20oC) before being sectioned into 2-mm thick parallel slices from apex to the 
atrioventricular groove. Thereafter, the slices were stained for 15 min in 1% triphenyltetrazolium chloride (TTC) 
in phosphate buffer (pH 7.4) at 37 °C, followed by fixation in 4% formalin to enhance the stain contrast. Using a 
computerized planimetry program (Planimetry+ v2.0; ENK, Norway), the area of the left ventricle (LV), risk zone 
(AAR) and infarcted area were determined and multiplied by slice thickness to yield estimated volumes. Infarct 
size (IS) is expressed as the infarct volume/risk volume ratio (%). There were no significant differences between 
the different treatment groups in the relative volume of the area at risk (AAR/LV) (Table 1). A significant reduction 
in LVDP, CF and RPP after 5 min of regional ischemia confirmed that all groups obtained similar and expected 
degrees of ischemia relative to baseline (Table 2). Furthermore, there were no differences between groups with 
regards to recovery of LVDP, CF, HR or RPP during reperfusion (Table 2). The latter may be due to persistent 
stunning [6]. 
Immunoblot analysis 
Myocardial phosphorylation of Akt at Ser473, STAT-3 at Ser727 and GSK3β at Ser9 (Cell Signaling Technology, 
USA) in the area at risk were analysed by SDS-PAGE electrophoresis and WB analysis as previously described 
[7]. The tissue was homogenized in lysis buffer (20mM Tris-Hcl, 330mM Sucrose, 2mM EDTA and a protease 
inhibitor cocktail tablet (Roche Diagnostic)) and protein concentration was determined using a Bradford protein 
assay (Thermo Scientific). 40 µg of protein per sample were separated on 8-16% polyacrylamide-SDS gels 
(Thermo Scientific) and electrophoretically transferred onto PVDF (polyvinyl difluoride) membranes (Thermo 
Scientific). After transfer, membranes were activated in methanol, blocked in dry-milk, probed with primary 
antibody over night at 4°C followed by secondary antibody for one hour at room temperature. Western blots were 
developed by using an enhanced chemiluminescence detection system (Thermo Scientific) and band density 




Values are presented as mean ± standard error of the mean (s.e.m). Infarct size, AAR/LV and protein 
phosphorylation were tested for group differences by one way analysis of variance (ANOVA) combined with 
Fisher’s post hoc test. Comparisons of LVDP, CF, HR and RPP between groups were tested with mixed ANOVA 
combined with Tukey’s post hoc test for any significant differences. We tested stabilization vs. regional ischemia 
to confirm both adequate ischemia within groups and equal degree of ischemia between groups, and tested % 
recovery of 18 min stabilization at 5, 30 and 120 min of reperfusion to determine any differences after treatment. 
All statistics were performed in IBM SPSS (version 20.0.0). A value of p<0.05 was considered statistically 
significant. 
RESULTS 
Combination of Insulin and Ischemic Postconditioning Abrogates Cardioprotection  
In this study we confirmed previous results where administration of insulin [0.3 mU/ml] for the first 15 minutes 
of reperfusion [8] or 3x30s ischemic postconditioning at the onset of reperfusion [12] significantly reduced infarct 
size compared to controls (Ins 33.5±3.4% or IPost 33.5±3.3% vs. Ctr 54.7±6.8%, p<0.01) (Fig. 2). Both treatments 
were associated with a significant increase in phosphorylated Akt, GSK3β and STAT3 vs. Ctr (Fig. 3A-C). 
Surprisingly, not only did we not get any additional reduction in infarct size when combining insulin with IPost, 
but the infarct sparing effect of the separate treatments was lost altogether (Ins + IPost 59.5±3.4% vs. Ctr 
54.7±6.8%, ns) (Fig. 2). This was accompanied by significantly blunted levels of phosphorylated Akt, GSK3β and 
STAT3 (Fig. 3A-C).    
Combination of GSK3β-inhibition and Ischemic Postconditioning Abrogates Cardioprotection  
As crucial steps in RISK and SAFE signaling were abrogated with the combination of insulin and IPost, we wanted 
to bypass these kinases by targeting the putative common signaling kinase in both pathways, i.e. GSK3β. The 
ATP-competitive inhibitor of GSK3β, SB415286, was applied for the first 15 min of reperfusion, and it 
significantly reduced infarct size compared to controls (SB41 30.5±3.0% vs. Ctr 54.7±6.8%, p<0.05) (Fig. 2). As 
expected, this treatment alone had no effect on the phosphorylation of Akt, GSK3β or STAT3 (Fig. 3A-C), but 
when it was combined with IPost, this also abolished the infarct sparing effect (SB41 + IPost 50.2±6.6% vs. Ctr 
54.7±6.8%, ns) (Fig. 2), and, even more surprisingly, significantly reduced the phosphorylation of Akt, GSK3β 
and STAT3 compared to IPost (Fig. 3A-C). 
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Combination of Insulin and GSK3β inhibition did not lead to Additional Cardioprotection  
The combination of insulin and the GSK3β inhibitor SB415286 eluted directly in the drug reservoir and 
administered for 15 min at reperfusion, did not reduce infarct size compared to either treatment alone (Ins 
33.5±3.4% or SB41 30.5±3.0% vs. Ins + SB41 26.7±3.5%, ns) (Fig. 2). The phosphorylation level of GSK3β and 
STAT3 was similar as insulin treatment alone (Fig. 3B and C), while the Akt phosphorylation was lower than the 
insulin group, but significantly higher than the SB41 group (Fig. 3A) (GSK3β phosphorylation by insulin is not 
affected by SB41 [25]).  
DISCUSSION 
The present study verifies that insulin for 15 min at reperfusion reduces infarct size and signals via Akt, GSK3β 
and STAT3, as reported earlier [8-10]. Similar results were obtained using a 3x30s protocol of IPost, also in 
concordance with others [11]. The rational for combining these two treatments was a study in which insulin (and 
GSK3β inhibition), in contrast to ischemic conditioning, was demonstrated to induce cardioprotection 
independently of mitochondrial ATP-sensitive potassium (mKATP) channels and subsequent release of reactive 
oxygen species (ROS) [5]. Opening of mKATP-channels has been demonstrated to be a vital trigger in many 
cardioprotective treatments (reviewed in [12]), including IPost [13], and thus it would seem logical to combine 
insulin and IPost. Much to our surprise, this combined treatment completely abolished any infarct sparing effect, 
and event that is not straightforward to explain. However, there is some evidence to suggest that protective 
mitochondrial signaling requires a cyclic activation at reperfusion: Bradykinin or direct mKATP channel opening 
by diazoxide is ineffective when applied continuously for 3 min at reperfusion, but reduces infarct size when 
applied for 5x10s (same as their IPost protocol) [14]. We replicated these findings with insulin: 1 or 5 min 
continuous insulin treatment was ineffective, but 3x30s intermittent infusion (InsPost) reduced infarct size to a 
similar degree as IPost, acting via mKATP and ROS [15]. Continuous (15 min) insulin treatment also signals via 
mKATP channels (results not shown). Thus, the signaling pathways in insulin and IPost induced cardioprotection 
may be more overlapping than initially thought. One could therefore speculate whether intermittent treatment 
activates and opens the mKATP channel faster than shorter continuous treatment, and/or that intermittent and longer 
continuous insulin produces just the right type and/or amount of ROS in the right intracellular compartment to 
induce protection from reperfusion induced injury. However, this still does not fully explain why the combination 
of two, seemingly channel-activating cardioprotective treatments like IPost and continuous insulin (15min), would 
be detrimental. Nevertheless, our data show a clear link between the loss of protection and diminished 
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phosphorylation of important RISK and SAFE signaling components like Akt, GSK3β and STAT3. The lack of 
protection in the shorter (1 or 5 min) insulin treatment groups also corresponded with reduced Akt phosphorylation 
[15]. Transient small bursts of cellular ROS may play an important role in insulin mediated signaling [16], while 
high concentration of ROS may attenuate insulin-mediated phosphorylation of Akt and GSK3β [17]. We therefore 
speculate whether the combination of IPost with insulin generates a larger, and hence, adverse ROS concentration 
causing blunted RISK and SAFE signaling, and loss of protection.  
Based on our current knowledge from the literature, it is quite difficult to conceive how the combination of IPost 
with either GSK3β-inhibition (or insulin) would be detrimental. Phosphorylation, and thus, inhibition of GSK3β, 
a central, integrative kinase downstream of both Akt and STAT3, is crucial for cardioprotection from IPost [18], 
IPC [19], opioids [20], erythropoietin [21] and adenosine [22]. In addition, pharmacological inhibition of GSK3β 
has been demonstrated to reduce infarct size when administered prior to ischemia or five min before reperfusion 
[20]. Our results, where the use of an ATP competitive GSK3β inhibitor, SB415286, for 15 min at reperfusion 
reduced the infarct size is thus in concordance with previous findings. By directly targeting GSK3β, any upstream 
interference should be bypassed and a potential benefit of combining GSK3β inhibition with IPost should be 
revealed. However, SB41 also reversed the infarct sparing effect of IPost when the two treatments were combined. 
SB41 had no impact on Akt or STAT3 phosphorylation, as expected for a downstream kinase, but it did reduce 
the IPost induced phosphorylation of Akt and STAT3 when the two treatments were combined. This is a surprising 
finding and implies that there is some sort of cross-talk between GSK3β and more proximal kinases in RISK and 
SAFE. Although much evidence suggests that GSK3β is one of the last steps in the signaling cascade before 
inhibition of mPTP, some evidence suggests that mKATP channels are downstream of GSK3β inhibition [23]. In 
addition, Downey and co-workers have extensively studied signaling in IPC and hypothesized that the ROS signal 
produced from opening of mKATP channels induce a PKC mediated increase in affinity of the adenosine A2b 
receptors, which in turn, is responsible for higher levels of RISK activation at reperfusion [24]. Further research 
is needed to establish if this link between mitochondrial signaling and upstream RISK (and SAFE) signaling 
pertains to IPost as well.  
The combination of insulin and GSK3β inhibition did not further decrease infarct size compared to either treatment 
alone. Activity assays from muscle and fat cell cultures have revealed greater inhibition of GSK3β by SB41 than 
by insulin [25], and thus we hypothesized an even greater reduction of infarct size. When this appears not to be 
the case, it would seem that insulin’s inactivation of GSK3β already maximally exploits the potential for reduction 




First, although the Langendorff perfused rat heart represents a good compromise between quantity and quality of 
data, it is far from the in vivo setting with respects to oxidative stress, neuro-hormonal influence and several other 
components that may potentially influence the results obtained in the present study. Second, there appear to be 
differences in signaling pathways between rats and other species, and specifically a recent study of remote ischemic 
preconditioning in humans found STAT5 to be activated [26], unlike the more extensively studied STAT3 in 
rodents. Third, the present study was performed on young, healthy animals, while most myocardial infarct patients 
have comorbidities such as diabetes and hypertension. Studies on animal models of type 2 diabetes and post-infarct 
remodeling has shown impaired PI3K-Akt signaling [27, 28], and thus it is uncertain if myocardial signaling at 
reperfusion in human patients will behave similarly.    
 
CONCLUSION 
The present study demonstrated that direct pharmacological treatment of IRI by insulin or GSK3β-inhibition 
somehow interferes with the infarct sparing effect of the endogenous ischemic postconditioning mechanism, and 
that this coincides with attenuation of RISK and SAFE signaling. This could have important implications for 
clinical trials with ischemic postconditioning in which combination with insulin, or other agents inducing GSK3β-
inhibition, could bereave patients of this treatment’s clinical benefit.  
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Table 1 Ratio of area at risk (AAR) and left ventricle (LV) volumes. 
Group N AAR/LV (%) 
Ctr 8 41.5 ± 2.5 
Ins 13 42.2 ± 2.5 
IPost 6 49.1 ± 3.0 
Ins+IPost 8 44.5 ± 2.5 
SB41 11 41.1 ± 2.8 
Ins+SB41 6 32.7 ± 4.8 
IPost+SB41 9 44.6 ± 5.2 



















Table 2 Functional parameters recorded during the experimental protocol. 
  Group 18' Stab 5' RI 5' Rep 30' Rep 120' Rep 
                % recovery of 18' Stab 
LVDP 
mmHg 
Ctr 133 ± 11 70 ± 8 # 82 ± 10 65 ± 7 41 ± 6 
Ins 161 ± 10 88 ± 7 # 80 ± 5 74 ± 4 52 ± 4 
IPost 131 ± 8 58 ± 11# 69 ± 6 68 ± 4 50 ± 5 
Ins+IPost 148 ± 16 69 ± 8 # 76 ± 8 77 ± 15 51 ± 6 
SB41 161 ± 10 84 ± 13# 60 ± 4 63 ± 5 51 ± 3 
Ins+SB41 163 ± 10 89 ± 13# 74 ± 5 69 ± 4 52 ± 5 
IPost+SB41 143 ± 5 75 ± 5 # 80 ± 7 74 ± 5 61 ± 5 
CF 
ml min-1 
Ctr 11.5 ± 1.3 7.4 ± 0.9# 88 ± 8 82 ± 6 52 ± 6 
Ins 12.8 ± 0.9 7.6 ± 0.4# 99 ± 9 81 ± 7 62 ± 7 
IPost 13.1 ± 1.0 7.8 ± 1.1# 88 ± 7 74 ± 8 70 ± 7 
Ins+IPost 13.3 ± 1.6 7.6 ± 0.6# 94 ± 10 84 ± 14 61 ± 6 
SB41 13.7 ± 0.8 8.0 ± 0.7# 68 ± 7 70 ± 4 53 ± 3 
Ins+SB41 14.9 ± 0.9 9.5 ± 1.1# 76 ± 9 78 ± 5 58 ± 5 
IPost+SB41 12.6 ± 1.2 6.8 ± 0.3# 99 ± 12 88 ± 5 67 ± 4 
HR 
beats min-1 
Ctr 279 ± 14 262 ± 26 97 ± 1 94 ± 1 91 ± 1 
Ins 276 ± 11 259 ± 13 84 ± 1 95 ± 3 85 ± 2 
IPost 319 ± 9 295 ± 17 95 ± 2 96 ± 3 94 ± 2 
Ins+IPost 283 ± 13 270 ± 17 92 ± 1 96 ± 1 91 ± 1 
SB41 302 ± 6 275 ± 9# 89 ± 1 100 ± 1 94 ± 1 
Ins+SB41 295 ± 12 286 ± 12 93 ± 1 103 ± 1 97 ± 1 
IPost+SB41 286 ± 12 258 ± 8 91 ± 1 104 ± 3 98 ± 2 
 Ctr 42349 ± 6003 17863 ± 2370# 67 ± 10 60 ± 8 35 ± 8 
 Ins 44577 ± 2813 22123 ± 1691# 73 ± 11 67 ± 5 48 ± 5 
 IPost 41681 ± 2078 17074 ± 3227# 62 ± 7 63 ± 5 46 ± 6 
RPP 
beats*mmHg Ins+IPost 42231 ± 5196 18290 ± 2049
# 62 ± 8 65 ± 13 48 ± 6 
 SB41 48933 ± 3055 22797 ± 3597# 45 ± 6 61 ± 5 47 ± 3 
 Ins+SB41 47066 ± 4132 23503 ± 3541# 56 ± 4 70 ± 3 50 ± 4 
 IPost+SB41 41125 ± 2489 19437 ± 1507# 66 ± 6 76 ± 4 59 ± 4 
LVDP = left ventricular developed pressure (mmHg); CF = coronary flow (ml/min); HR = heart rate (beats/min); 
RPP = rate pressure product (beats/mmHg); Stab = stabilization; RI = regional ischemia; Rep = reperfusion. 







Fig. 1 Experimental protocol. Stab = stabilization; RI = regional ischemia; Open bars = buffer perfusion; Ctr = 
ischemia–reperfusion controls; Ins = insulin [0.3 mU/ml] for the first 15 min of reperfusion; IPost = ischemic 
postconditioning, 3x30s of global ischemia (GI); Ins + IPost =  insulin interrupted by ischemic postconditioning; 
SB41 = GSK3β inhibitor SB415286 [3 µM] for the first 15 min of reperfusion; Ins + SB41 = co-administration of 
insulin and GSK3β inhibitor for the first 15 min of reperfusion. IPost + SB41 = SB415286 interrupted by ischemic 
postconditioning; Arrows indicates time points for tissue collection from a parallel set of hearts. 
Fig. 2 Infarct size. Infarct size is expressed as percentage of the area at risk. SB41 [3 µM] and insulin [0.3 mU/ml] 
reduced infarct size with ~40% compared to controls (Ctr). The combination of insulin and SB41 did not result in 
any further reduction of infarct size compared to the treatments alone. IPost reduced infarct size by ~36% compared 
to controls. However, combining IPost with either insulin [0.3 mU/ml] or SB41 [3 µM] completely abrogated the 
infarct-sparing effect of IPost. Bars represent mean ± SEM. N≥6 in each group. *p<0.05 vs. control group, ¤ 
p<0.05 vs. IPost, $ p<0.05 vs. Ins, # p<0.05 vs. SB41. 
Fig. 3 Phosphorylation status of myocardial Akt, GSK3β and STAT3. Representative immunoblots (top) and 
densitometric analysis (bottom) of (A) total and phosphorylated Akt (Ser473), (B)  total and phosphorylated GSK3β 
(Ser9) and (C) total and phosphorylated STAT3 (Ser727). GAPDH serves as loading control. Reperfusion treatment 
with either Ins, SB41 or IPost lead to increased levels of phosphorylated Akt, GSK3β and STAT3, while the 
combination of Ins or SB41 and IPost reduced this phosphorylation. SB41 alone had no effect on phosphorylated 
Akt, GSK3β or STAT3. The combination of Ins and SB41 caused a significant elevation in Akt and GSK3β 
phosphorylation as compared to control, while STAT3 phosphorylation was not significantly elevated as compared 
to control, but not different from the Ins group either. InsB = baseline insulin perfusion for 20 min served as positive 
control. Ctr = KHB perfused ischemia-reperfusion. Densitometric analysis of total and phosphorylated proteins 
expressed in arbitrary units (AU) where the phosphorylated proteins are expressed as a ratio of the corresponding 
total proteins. Bars represent means ± S.E.M. N ≥ 3 in each group. Significant differences (P < 0.05) are as denoted 
in the bar graphs. 
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